Fundamental and practical aspects of coronary artery calcification

Barbarash O. L., Kashtalap V. V., Shibanova I. A., Kokov A. N.

The review article summarizes the results of studies on the pathogenesis, as well as the clinical and prognostic role of coronary artery calcification (CAC) in coronary artery disease. The modern views of cardiologists, surgeons and general practitioners on the comorbidities manifested by CCA are presented. The modern ideas on the relationship between atherogenesis, CCA and bone resorption are described; groups of informative biological markers reflecting the severity of process are identified. Modern diagnostic methods for the detection and study of CCA are highlighted, their advantages and limitations are indicated. The effect of atherosclerosis treatment on coronary calcification and osteopenia are discussed. Further prospects and lines of research in this area are presented.

Key words: coronary calcification, mechanisms of arterial calcification, diagnosis of arterial calcification, myocardial revascularization

Relationships and Activities. The study was conducted as part of the fundamental theme “Multifocal atherosclerosis and comorbidities. Features of diagnosis, risk management in a large industrial region of Siberia”, approved by the Ministry of Science and Higher Education of the Russian Federation.

Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia.

Barbarash O. L. ORCID: 0000-0002-4642-3610, Kashtalap V. V.* ORCID: 0000-0003-3729-616X, Shibanova I. A. ORCID: 0000-0001-8418-8140, Kokov A. N. ORCID: 0000-0002-7573-0636.

*Corresponding author: v_kash@mail.ru

Received: 09.07.2020
Revision Received: 23.07.2020
Accepted: 30.07.2020

For citation: Barbarash O. L., Kashtalap V. V., Shibanova I. A., Kokov A. N. Fundamental and practical aspects of coronary artery calcification. Russian Journal of Cardiology. 2020;25(S3):4005. (In Russ.) doi:10.15829/1560-4071-2020-4005
In recent years, the problem of coronary artery calcification (CAC) has been of concern to many specialists. Interventional and cardiovascular surgeons consider this problem from the perspective of the specific coronary anatomy, which presents difficulties in selecting the revascularization method, and often specifies the failure of percutaneous coronary intervention (PCI) [1]. Cardiovascular surgeons consider CAC as a factor of a possible aorta calcification associated with the difficulties when performing direct myocardial revascularization [2]. Radiologists focus on the need to choose the most informative and accessible method for detecting and quantifying CAC [3]. Cardiologists consider patients with CAC as a group of very high cardiovascular risk not only due to coronary artery lesion, but also due to additional comorbidity in these patients — bone, renal, metabolic [4, 5], and consider the need for medication intervention in this process [6]. However, the largest number of publications on CAC in recent years has been devoted to the discussion of developmental pathways, the choice of the most sensitive and specific biological markers, as well as approaches to managing the risks of its development [6, 7]. It should be noted that the lack of a unified point of view on these important issues, on the one hand, leads to dissatisfaction in the available research data, contradicting each other, on the other hand, it is an incentive to conduct new studies.

This review is devoted to modern papers on CAC, relevant points of view on the pathways, and clinical significance of CAC based on our own studies carried out at the Research Institute for Complex Issues of Cardiovascular Diseases.

Atherosclerosis and arterial calcification are interrelated synchronous pathological processes. It is believed that atherogenesis at all stages is in one way or another accompanied by impaired calcium and phosphorus metabolism and calcium deposition in the atherosclerotic plaque or in the arterial media [8]. At the same time, there is still no consensus about whether arterial calcification is the end stage of atherosclerosis, or is the development of CAC possible at its initial stages? Modern imaging technologies demonstrate that calcium plays a different role throughout the life of an atherosclerotic plaque. CAC can be a reflection of various pathological conditions, being present during the formation of an unstable, vulnerable plaque and during periods of its stabilization — delipidation, for example, with statin therapy. Therefore, at different steps of atherogenesis, the clinical consequences of CAC can be very variable and diverse [3].

At present, there is no consensus on the extent to which calcification of an atherosclerotic plaque can provoke or prevent its rupture. For many years, the generally accepted opinion was that a calcified plaque is a factor of atherosclerosis stability [9]. However, the notion that CAC prevents plaque destabilization is currently being revised. It has been shown on mouse models that large calcium deposits in the coronary arterial intima affected by atherosclerosis can be related with plaque rupture followed by myocardial infarction (MI) [10]. Another evidence of the unfavorable role of CAC on the plaque is the fact that patients with severe calcification have a higher platelet reactivity and, in general, a higher thrombogenicity [11], which indicates the vulnerability of seemingly stable atherosclerotic plaques. In addition, using intravascular ultrasound (IVUS), it was shown that even microcalcification of the atherosclerotic plaque capsule increases its tension and provokes the instability. At the same time, not all calcifications in the arteries are associated with an increased cardiovascular risk; it is also necessary to assess the distribution and morphology of calcium in atheroma [12].

For a long time, the assessment of CAC using the calcium index (CI) when performing multislice computed tomography (MSCT) was used exclusively for stratification of cardiovascular risk in the general population. It was believed that in patients with documented coronary atherosclerosis, to assess the severity of disease, it is sufficient to determine only the anatomical features of coronary atherosclerosis, the presence and severity of stenosis. The clinical and prognostic value of CAC in patients with documented coronary artery disease (CAD) was not considered [13]. At the same time, in recent years, more and more data have been accumulating that CAC is diagnostically important additional information for patients with CAD. CAC is a reflection of the anatomical severity of coronary atherosclerosis, a factor of severe comorbidity status, and, possibly, an additional marker of the clinical severity and unfavorable outcome of the disease [6]. CAC detection is especially important when selecting the optimal method of myocardial revascularization.

**CAC — the view of a cardiologist and therapist.** Calcification of any arteries without severe hormonal disorders and end-stage renal failure is an objective marker of aging. An increase in the area of calcium deposits in the aorta, aortic valve cusps, and coronary arteries is recorded in persons over 60 years of age. Aortic calcification leads to a change in its elasticity, the development of left ventricular hypertrophy followed by heart failure. With aortic calcification, the pulse wave velocity, systolic blood pressure, and pulse pressure increase. Aortic valve calcification leads to the development of degenerative aortic stenosis. In the coronary arteries, calcium deposits reduce vasodilatory effects and affect the stability of atherosclerotic plaques in one direction or another [3].
CAC is more commonly diagnosed in older men. At the age of 70 and older, CAC is detected in more than 90% of men and 67% of women [7]. At the same time, the severity of arterial calcification is higher in men compared to women up to the sixth decade of life, and then CAC has no sex differences [14]. The menopause onset is associated with a 3-fold increase in the risk of detecting arterial calcification [15].

A number of studies revealed racial differences in the frequency and severity of CAC, which can specify the differences in clinical manifestations and outcomes of atherosclerosis. In the Multi-Ethnic Study of Atherosclerosis (MESA) [16], 6814 individuals without a history of cardiovascular disease of various races (whites, African Americans, Hispanics, Chinese) aged 45 to 84 years were assessed. The prevalence of CAC (Agatston score >0) in these 4 ethnic groups in men was 70.4%, 52.1%, 56.5% and 59.2% (p<0.001), and among women — 44.6%, 36.5%, 34.9% and 41.9% (p<0.001), respectively. After adjusting for age, educational level, lipid profile, body mass index, smoking, diabetes, hyperten-

**Figure 1.** Cardiac MSCT with a quantitative assessment of coronary artery calcification. Voxels in the projection of coronary arteries with a density >130 Hounsfield units are defined as calcifications.
sion, statin use, sex and location of the research center, the relative risk (RR) of CAC, compared with the white race, was: for Africans — 0.78 (95% confidence interval (CI) 0.74–0.82); for Hispanics 0.85 — (95% CI 0.79–0.91) and for Chinese — 0.92 (95% CI 0.85–0.99). In addition, it was shown that the CAC severity in explanted hearts was higher in whites than in African Americans for every decade of life [17]. Several possible explanations for the higher prevalence of CAC in whites have been proposed. One of the possible reasons is the close relationship of calcification with a decrease in bone mineral density inherent in white people. It is known that African Americans have higher bone mineral density than whites, and, as a result, less pronounced calcification of the arteries. Another explanation is the specific racial differences in genes responsible for calcium and phosphorus metabolism [17]. However, the exact genetic mechanisms of these differences has not been identified.

Diabetes is considered as risk factor (RF) for CCA. Chronic kidney disease, which is a comorbidity of diabetes, is also such a factor [6]. The role of carbohydrate metabolism disorders in the development of CAC was evaluated in 2076 patients. A higher level of glycated hemoglobin was associated with any CAC progression (increase >10 Agatston units) during 5-year follow-up (RR=1,51 95% CI 1.16–1.96) and the advanced progression of CAC (increase >100 Agatston units) (RR=2,42; 95% CI 1.47–3.99) [18]. Previous studies of autopsy material from individuals with sudden death have shown that patients with diabetes, compared with those without it, have a higher percentage of calcified plaques and higher severity of calcification. At the same time, plaque macrophage and T-cell infiltration were also more intense, which indicates the presence of chronic intravascular inflammation in diabetes, provoking the progression of plaque calcification as a repair mechanism [19].

In our previous studies, in patients with multivessel coronary artery disease, only 10% had a minimal CAC calculated by the Agatston score; severe CAC was diagnosed in more than half of the patients examined. The relationship between the severity of coronary calcification and the severity of coronary atherosclerosis was determined, which indicates the pathophysiological parallelism of atherogenesis and CAC [20].

According to other studies, CAC in the general population is directly related to adverse outcomes and is a much more accurate marker of future events than other RFs. However, it is still not clear whether this is due to the calcified plaque itself as a source of future events, or whether calcified plaques are exclusively markers of global cardiovascular risk. The most promising is the data of coronary imaging in combination with the medical history and clinical characteristics of patients. Recent studies suppose that CAC cannot be considered as a qualitative variable (yes/no), but rather its quantity, type, location of calcification, volume and density matter [8]. Thus, the future of CAC identification and its risk interpretation lies with instrumental methods, which will simultaneously characterize both quantitative and qualitative characteristics of CAC.

**CAC — the view of a diagnostic radiology specialist.** Currently, MSCT is the main method for diagnosing and quantifying CAC, which has high sensitivity and specificity. The beginning of the practical use of high calcification density in coronary arteries was laid by Arthur Agatston, who presented in 1990 a protocol for quantitative assessment of CAC using electron beam tomography [21]. The standardized technique, which is based on the verification of structures with a density >130 Hounsfield units, is actively used at the present time, but already on modern high-resolution multislice tomographs [22].

Quantification of CAC is one of the key tools in assessing the risk of fatal cardiovascular events for patients with suspected CAD and with an intermediate pretest probability of CAD. The severity of CAC, assessed by MSCT, can be used as a screening examination for moderate-risk people and as an additional criterion for risk stratification in asymptomatic patients regardless of traditional CAD RF (hypertension, diabetes, lipid metabolism disorders, etc.). CI is the mathematical derivative of the calcification area on each tomographic slice and the factor of its X-ray density. The total CI score in Agatston units (AU) is formed by summing the scores of each calcified lesion in all coronary arteries (Figure 1). Depending on the obtained values of the total coronary artery CI, 4 grades are distinguished: minimal (1-10 AU), mild (11-100 AU), moderate (101-400 AU) and severe (>400 AU) calcification. It has been proven that CI is closely related to the severity of coronary atherosclerosis [23] and the risk of acute coronary events [24]. Risk stratification of fatal coronary events is carried out by comparing the absolute values of a respondent’s individual CI and the 75th percentile of the population-based CI adjusted for age and sex [25]. The percentage of coronary artery involvement in the calcification process, the so-called calcium coverage score, also characterizes the severity of atherosclerotic lesions and is associated with diabetes and dyslipidemia [26].

The limitations of quantitative assessment of CAC are due to, albeit low, but still potentially unfavorable radiation exposure of a patient. In addition, cardiac arrhythmia, the inability to lie motionless during the scan and hold the breath do not allow for a reliable assessment.
In patients with CAD, pronounced CAC is often detected during coronary angiography. Before the administration of a contrast agent, it manifests as radiopaque shadows [27]. Directly during angiography, calcium deposits in the arterial wall manifest as heterogeneous intraluminal abnormalities. In such a situation, it is necessary to differentiate CAC from the manifestations of intracoronary thrombosis, which is rather difficult to do in the context of conventional coronary angiography. Thus, the effectiveness of coronary angiography in assessing arterial calcium is not optimal, especially in patients with signs of stent restenosis. The study by Mintz GS, et al. [28] showed that coronary angiography detects calcium only in 38% of cases; the possibility of detection depends on the severity of CAC.

A more informative method for CAC detection is IVUS and optical coherence tomography (OCT), which makes it possible to comprehensively assess the calcium deposit. Since calcium causes a reflection of ultrasound, CAC usually appears in the IVUS image as a hyperechoic arc combined with a deeper acoustic shadow. An early IVUS autopsy study reported a sensitivity of 90% and specificity of 100% for detecting calcified atherosclerotic plaque or clustered microcalcifications and lower accuracy for detecting isolated microcalcifications (<50 μm). These data were confirmed by further clinical studies that demonstrated a higher diagnostic value of IVUS compared with coronary angiography in CAC detection (73% and 38% of cases, respectively; p<0.001). However, the sensitivity of this method for the detection of calcifications with a small surface area (<0.05 mm²) did not exceed 65% [29]. In addition, the limitation of IVUS in CAC detection is the ability to visualize only the anterior edge of the calcification without reliable information about the calcification thickness (Figure 2).

A partial solution to the issue of quantifying the CAC is an integral indicator based on the calculation of calcification arc and length. But this approach does not reflect the true calcification given its depth. Thus, OCT has advantages in CAC detection in the form of a more accurate quantitative assessment of calcified plaque. In OCT, CAC is manifested as a low-signal area with a sharp luminal border [30]. OCT also provides data on the calcification area, thickness, length, and volume of calcification in three-dimensional space [31, 32] (Figure 3).

It has been proven that these characteristics of CAC allow predicting the success of balloon angioplasty and coronary stenting. It should be noted that IVUS and OCT methods can also be used to assess the end result of stenting, and the information content of OCT is higher [33].

Thus, there are currently various methods for detecting CAC. At the stage of cardiovascular risk assessment, the method of choice is coronary artery MSCT, in patients with documented CAD — IVUS and OCT, which allow one to quantitatively characterize the length and thickness of calcification, the involvement of the distal areas. Nevertheless,
the high availability and non-invasiveness of MSCT make this method promising for CAC assessment even in patients with CAD. Thus, in a cohort of patients with multifocal atherosclerotic lesions, ectopic coronary artery calcification according to MSCT is observed in 93% of patients, while most of them (73.5%) have moderate (101-400 AU) and severe (>400 AU) coronary calcification [4].

CAC — the view of an endovascular and cardiovascular surgeon. CA is one of four anatomical markers of the technical complexity of coronary interventions [1]. It is CAC that is associated with the maximum risk of intraoperative complications and long-term cardiovascular events.

Bourantas CV, et al. [34] showed that in PCI, patients with CAC are less likely to have complete myocardial revascularization than patients without CAC (48% vs 55.6%; p <0.001) and have a higher mortality risk during follow-up (10.8% vs 4.4%; p<0.001). It is important to note that the relationship between CAC and unfavorable outcome does not depend on the clinical manifestations of CAD and the type of implanted stents [27, 35, 36]. In the pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUTITY (Acute Catheterization and Urgent Intervention Triage Strategy) trials, PCI performed in patients with moderate to severe CAC were associated with a 62% increase in stent thrombosis and a 44% increase in ischemic target lesion revascularization [27].

Adverse clinical outcomes recorded in patients with CAC are associated with both comorbidities and increased technical complexity of PCI [37]. Typically, these lesions are less malleable with predilation. In patients with severe CAC, inadequate preparation of the calcified zone of the coronary artery for stent implantation increases the risk of stent loss, insufficient dilatation, or destruction. With pronounced CAC, the likelihood of no reflow phenomenon, dissection and perforation of the coronary artery during PCI is high. Upon implantation of drug-eluting stents (DES), the presence of CAC can damage the polymer on the stent and interfere with drug release [38].

Patients with severe CAC during PCI are characterized by higher values of markers of myocardial damage in the periprocedural period, which are a reliable criterion for an unfavorable long-term outcome of the disease [39]. It is known that the factors of a high probability of myocardial injury during PCI are advanced age and renal dysfunction, which reflects a patient with CAC [40]. It has been suggested that patients with higher severity of CAC should receive more intensive antithrombotic therapy after the procedure [41].

Coronary calcium is a marker of an unfavorable course of the postoperative period after coronary artery bypass grafting (CABG). One of the factors determining an unfavorable prognosis in this category of patients is severe calcification of the aorta, aortic valve, mitral annulus, which has an independent effect on the prognosis. There are very few studies on the effect of preoperative CAC on outcomes after CABG. In one of them, Ertelk K, et al. showed that CAC detected before CABG is an independent predictor of coronary events during 12 month follow-up [42]. During the first month after CABG, patients with severe CAC had perioperative MI 1.5 times more often than those without CAC. The authors of this study explain the presented results by the fact that CAC is associated with poor distal bed, endothelial dysfunction, and distal embolism. In addition, arterial calcification complicates the vascular anastomoses, increases the cardiopulmonary bypass duration, and reduces the likelihood of complete coronary revascularization. Coronary calcium, as well as aortic calcification during CABG, can increase the risk of bleeding and require more blood transfusion. CABG may reflect more severe atherosclerotic lesions in other vascular regions, which has an independent effect on CABG results. However, the low frequency of events over a short-term follow-up period in this analysis did not allow for firm conclusions.

In another study evaluating the role of CAC in the prognosis of patients undergoing CABG, one of the reasons for the unfavorable outcome after myocardial revascularization, the authors note the more frequent development of vein graft calcification in patients with baseline calcification of native coronary arteries [43].

Our study assessed the clinical and prognostic significance of CCA in patients with CAD after CABG. According to MSCT, more than half of the patients had signs of severe CAC [20]. The risk of adverse cardiovascular events (fetal and non-fetal acute vascular events and recurrent angina) within three years after CABG was associated with baseline high values of bone metabolism biomarkers (osteocalcin and parathyroid hormone) [44].

A retrospective analysis of the SYNTAX trial presents 5-year results of CABG in patients with varying grades of CAC assessed by coronary angiography. The authors concluded that severe CAC in patients with CABG, in contrast to patients with PCI, is not associated with a higher risk of incomplete revascularization and is not an independent predictor of mortality from MI and other cardiovascular events, but is an independent predictor of all-cause mortality. Higher mortality rates were observed in the period from 1 to 5 years after surgery, rather than...
during the first postoperative year. There were no differences in the incidence of acute coronary events, which meant that there was a higher baseline cardiovascular and renal comorbidity in patients with CAC. These results considered that CABG is more effective method of myocardial revascularization for patients with CAD and severe CAC than PCI. However, the patient with CAC remains at high risk of unfavorable outcome after CABG [45].

CCA — the view of a clinical pathophysiologist. The importance of assessing calcification in terms of clinical presentation and prognosis specifies the relevance of studying biomarkers reflecting calcification. For many years, the calcification of an atherosclerotic plaque was considered as a passive, degenerative phenomenon with the mechanisms underlying the bone tissue formation [46]. At the same time, in recent years, a concept has been created that characterizes CAC as an active process, which is based on a systemic inflammatory response, typical for patients with metabolic syndrome or with renal dysfunction [3, 47].

In general, CAC is the deposition of mineralized calcium in the endothelium or in the intercellular space of coronary artery media. It is assumed that lysosomes, mitochondria, intercellular substance (glycosaminoglycans), elastic and collagen fibers can be a matrix for calcification [48]. Ectopic vascular calcification usually consists of bone-like components: phosphates, calcium salts, hydroxyapatite, type I collagen, osteopontin, bone morphogenetic protein, osteocalcin, osteonectin, and matrix Gla protein [49]. This is facilitated by a number of factors in the initiation and progression of atherosclerosis: dyslipidemia, activation of oxidative stress markers (C-reactive protein), interleukins and growth factors. This, in turn, leads to endothelial dysfunction, a local increase in metalloproteinase levels, and the activation of the RANKL/RANK/OPG system and release of cathepsins with the formation collagen fibers as centers of future calcification in the atherosclerotic plaque. It is assumed that these are the common pathways of aortic and coronary calcification, as well as disorders of bone mineral density [50].

Factors of subclinical inflammation play a key role in the development of both CAC and bone mineral density disorders [51]. Inflammatory reactions are local (tissue) and systemic in nature; the general proinflammatory response is well reflected by an increase in C-reactive protein and a number of interleukins (-1, -6, -12, -18). The high activity of systemic inflammation with atherogenesis is persistent and leads to fibrosis and calcification in the intercellular subendothelial space of arteries [52]. In parallel, osteoclasts are activated in the bone tissue and complex hormonal changes are observed. In bone, the high rate of tissue inflammation is reflected in the activation of RANK/RANKL/OPG system and inhibition of anti-inflammatory factors such as fetuin-α [53]. In the early stages of CAC, inflammatory cytokines activate osteogenic differentiation and mineralization of the vascular wall; at next stages, an increase in mineralization intensity is accompanied by a decrease in the content macrophage levels and further destruction of bone tissue [51]. The markers of bone destruction persistence include osteocalcin, calcitonin, cathepsin, an increase in insulin level, a decrease in levels of androgens in men and estrogens in women [54]. The same markers were shown to be associated with the severity of CAC and aortic calcification [55]. According to our own data, the common pathogenic factors for atherosclerosis and osteoporosis in men with CAD were low levels of vitamin D and ionized calcium, increased levels of alkaline phosphatase, phosphorus and osteocalcin [5].

Therefore, it is relevant to discuss the role of lipid-lowering therapy in the development of CAD and osteopenia. According to a number of authors, the use of statins is associated with the stabilization of atherosclerotic plaque due to an increase in fibrous capsule density and the number and size of calcifications in the plaque [56]. At the same time, CAC necessarily passes the vulnerability stage, when the risk of rupture and erosion of the capsule is especially high due to calcification foci increase. The effects of statins on osteopenia are the subject of scientific debate. A number of authors discuss possible sex differences in the effects of statin therapy on osteoporosis. Nevertheless, a significant anti-inflammatory effect of statins has been proven, both in terms of local reactions and systemic ones [57]. Some authors suggest, in addition to statins, the use of bisphosphonates and chelating agents to slow down the bone resorption and CAC progression [58].

Thus, the processes and mechanisms of CAC are a difficultly regulated pathophysiological phenomenon, which simultaneously reflects the activity of atherogenesis and disorders of bone mineral density. Identification of informative molecular markers and factors will make it possible in the future to develop effective strategies for medication managing the risk of its progression and individual prevention programs to improve the quality of life and life expectancy in patients with CAD.

Conclusion

The search for new mechanisms responsible for development and progression of atherosclerosis is urgent. CAC is probably one of the areas, the development of which can help in determining the most
important diagnostic criteria for the severity and prognosis of CAD. Identification of the most sensitive biomarkers of CAC will be the basis not only for additional risk stratification of CAD and assessment of comorbidity, but also for the search for promising targets for prevention and treatment of atherosclerosis.

References

1. De Maria GL, Scarsini R, Adrian P, Banning AP. Management of Calcific Coronary Artery Lesions Is it Time to Change Our Interventional Therapeutic Approach? Am J Cardiol Intv. 2019;12:1465-78. doi:10.1016/j.jcin.2019.03.039.
2. John R, Choudhri AF, Weinberg AD, et al. Multicenter review of preoperative risk factors for stroke after coronary artery bypass grafting. Ann Thorac Surg. 2000;69(1):30-6. doi:10.1016/s0003-4975(99)01309-0.
3. Andrews J, Psaltis PJ, Bartolo BAD, et al. Coronary arterial calcification: a review of mechanisms, promoters and imaging. Trends Cardiovasc Med. 2018;28:491-501.
4. Masenko VL, Kokov AN, Semenov SE, Barbarash OL. Noninvasive evaluation of density of coronary and carotid calcification in patients with type 2 diabetes mellitus. Journal of radiology and nuclear medicine. 2018;9(6):310-8. (In Russ.). doi:10.20862/0042-4676-2018-9-6-310-318.
5. Raskina TA, Voronkina AV, Letaeva MV, et al. Relationship between coronary artery calcification and osteopenic syndrome in men with coronary heart disease. Modern Rheumatology Journal. 2016;10(2):31-6. (In Russ.). doi:10.14412/1996-7012-2016-2-31-36.
6. Barbarash OL, Zykov MV, Hryachkova ON, et al. Pathogenetic mechanisms of comorbidity formation in coronary heart disease: atherosclerosis, renal dysfunction and mineral bone disorders. Novosibirsk, Nauka. 2019. p. 228. (In Russ.). ISBN: 978-5-02-038842-0.
7. Madhavan MV, Tarigopula M, Mintz GS, et al. Coronary artery calcification: pathogenesis and prognostic implications. J Am Coll Cardiol. 2014;63:1703-14. doi:10.1016/j.jacc.2014.01.017.
8. Shaw LJ, Narula J, Chandrashekhar Y. The never-ending story on coronary calcium: is it predictive, punitive, or protective? J Am Coll Cardiol. 2015;65:1283-5. doi:10.1016/j.jacc.2015.02.024.
9. Nicoll R, Henein MV. Arterial calcification: friend or foe? Int J Cardiol. 2013;167(2):322-7. doi:10.1016/j.ijcard.2012.06.010.
10. Orita Y, Yamamoto H, Kohno N, et al. Role of osteoprotegerin in arterial calcification: development of new animal model. Arterioscler. Thromb. Vasc. Biol. 2007;27:2058-64. doi:10.1161/ATVBAHA.107.147868.
11. Borrisooff Ji, Joosen IA, Versteylen MO, et al. Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis. J Am Coll Cardiol Img. 2012;5:1201-10. doi:10.1016/j.jcmg.2012.01.023.
12. Mintz GS. Intravascular imaging of coronary calcification and its clinical implications. J Am Coll Cardiol Img. 2015;8:46-17. doi:10.1016/j.jcmg.2015.02.003.
13. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. Eurointervention. 2005;1(2):219-27.
14. Otsuka F, Sakakura K, Yahagi K, et al. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler Thromb Vasc Biol. 2014;34:724-36. doi:10.1161/ATVBAHA.113.302642.
15. Burke AP, Farb A, Malcom G, Virmani R. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis. Am Heart J. 2001;141:558-62. doi:10.1067/mhj.2001.09946.
16. Bild DE, Detrano R, Peterson D, et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2005;111:1313-20. doi:10.1161/01.cir.0000157730.94423.4b.
17. Huang CC, Lloyd-Jones DM, Guo X, et al. Gene expression variation between African Americans and whites is associated with coronary artery calcification: the multiethnic study of atherosclerosis. Physiol Genomics 2011;43:836-43. doi:10.1152/physgeno-00243.2010.
18. Carson AP, Steffes MW, Carr JJ, et al. Hemoglobin a1c and the progression of coronary artery calcification among adults without diabetes. Diabetes Care. 2015;38:66-71. doi:10.2337/dc14-0360.
19. Burke AP, Koloidje FD, Zieske A, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266-71. doi:10.1161/01.ATV.0000131783.74034.97.
20. Barbarash O, Lebedeva N, Kokov A, et al. Decreased cathepsin K plasma level may reflect an association of osteopenia/osteoporosis with coronary atherosclerosis and coronary artery calcification in male patients with stable angina. Heart, Lung and Circulation. 2016;25(7):691-7. doi:10.1016/j.hlc.2016.02.002.
21. Agatston A, Janowicz W, Hildner F, et al. Quantification of coronary artery calcium ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827-33. doi:10.1016/j.jcmg.2012.01.023.
22. Kachelriess M, Ulzheimer S, Kalender W. ECG-correlated image reconstruction from subsecond multislice spiral CT scans of the heart. Med Phys. 2000;27:1881-902. doi:10.1118/1.1286552.
23. Kokov AN, Maluta EB, Masenko VL, et al. Evaluation of coronary artery lesion in men with osteopenic syndrome and coronary artery disease. Therapeutic archive. 2014;86(3):65-70. (In Russ.)
24. Raggi P, Callister TO, Cool B, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation. 2000;101(8):850-5. doi:10.1161/01.cir.101.8.850.
25. Budoff M, Achenbach S, Blumenthal R, et al. Assessment of coronary artery disease by cardiac computed tomography. Circulation. 2006;114:1761-91. doi:10.1161/CIRCULATIONAHA.106.178458.
26. Brown ER, Kronmal RA, Bluemke DA, et al. Coronary calcium coverage score: determination, correlates, and predictive accuracy in the Multi-Ethnic Study of Atherosclerosis. Radiology. 2008;247(3):669-75. doi:10.1148/radiol.2473071469.
27. Généreux P, Madhavan MV, Mintz GS, et al. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. J Am Coll Cardiol. 2014;63:1845-54. doi:10.1016/j.jacc.2014.01.034.
28. Mintz GS, Popma JJ, Pichard AD, et al. Patterns of calcification in coronary artery disease. A statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation. 1995;91:1959-65. doi:10.1161/01.cir.91.7.1959.
29. Friedrich GJ, Moes NY, Mühlberger VA, et al. Detection of intraluminal calcium by intracoronary ultrasound depends on the histologic pattern. Am Heart J. 1994;128(3):435-41. doi:10.1016/0002-6703(94)90614-9.
30. Sharma SK, Vengrenyuk Y, Kini AS. IVUS, OCT, and coronary artery calcification: is there a bone of contention? J Am Coll Cardiol. 2017;10:880-2. doi:10.1016/j.jcmg.2017.06.008.
31. Fujino A, Mintz GS, Matsumura M, et al. A new optical coherence tomography-based calcium scoring system to predict stent under-
expansion. EuroIntervention. 2018;13:e2182-9. doi:10.4244/EIJ-D-17-00962.

32. Krishnamoorthy P, Vengrenyuk Y, Ueda H, et al. Three-dimensional volumetric assessment of coronary artery calcification in patients with stable coronary artery disease by OCT. EuroIntervention. 2017;13:312-9. doi:10.4244/EIJ-D-16-00139.

33. Räber L, Mintz GS, Koskinas KC, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. EuroIntervention. 2018;14:656-77. doi:10.1093/eurheartj/ehy285.

34. Bourantas CV, Zhang YJ, Garg S, et al. Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. Heart. 2014;100:1158-64. doi:10.1136/heartjnl-2013-305180.

35. Généreux P, Redfors B, Witzenbichler B, et al. Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. Int J Cardiol. 2017;231:61-7. doi:10.1016/j.ijcard.2016.12.150.

36. Huisman J, van der Heijden LC, Kok MM, et al. Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: A patient-level pooled analysis from TWENTE and DUTCH PEERS. J Cardiol. 2017;69:660-5. doi:10.1016/j.jcc.2016.06.010.

37. Mayorov GB, Kurbanov SK, Vasova EE, et al. Calcification in coronary heart disease: issues of diagnosis, prognosis and choice of treatment. Russian Cardiology Bulletin. 2018;4:4-10. (In Russ.) doi:10.17116/Cardiobulletin2018130414.

38. Kunyama N, Kobayashi Y, Yamaguchi M. Usefulness of rotational atherectomy in preventing polymer damage of everolimus-eluting stent in calcified coronary artery. J Am Coll Cardiol Intv. 2011;4:588-89. doi:10.1016/j.jcin.2011.01.017.

39. Kappetein AP, Serruys PW, Sabik JF, et al. Design and rationale for a randomized comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. EuroIntervention. 2016;12:861-72. doi:10.4244/EIJ1217A141.

40. Zeitouni M, Silvain J, Guedenev P, et al. Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J. 2018;39:1100-9. doi:10.1093/eurheartj/ehx799.

41. Waters DD, Azar RR. The curse of target lesion calcification: still active after all these years. J Am. Coll. Cardiol. 2014;63(18):1855-6. doi:10.1016/j.jacc.2014.01.035.

42. Ertekin K, Généreux P, Mintz GS, et al. Impact of severity of coronary artery calcification on clinical events in patients undergoing coronary artery bypass grafting (from the Acute Catheterization and Urgent Intervention Triage Strategy trial). Am. J Cardiol. 2013;112:1730-7. doi:10.1016/j.amjcard.2013.07.038.

43. Castagna MT, Mintz GS, Ohlmann P, et al. Incidence, location, magnitude, and clinical correlates of saphenous vein graft calcification: an intravascular ultrasound and angiographic study. Circulation. 2005;111(9):1148-52. doi:10.1161/01.CIR.0000157160.69812.55.

44. Barbarash O, Zykov M, Kashlap V, et al. Increased Serum Parathyroid Hormone, Osteocalcin and Alkaline Phosphatase Are Associated with a Long-Term Adverse Cardiovascular Outcome after Coronary Artery Bypass Graft Surgery. Diagnostics. 2019;9(4):143. doi:10.3390/diagnostics9040143.

45. Bourantas CV, Zhang YJ, Garg S, et al. Prognostic Implications of Severe Coronary Calcification in Patients Undergoing Coronary Artery Bypass Surgery: An Analysis of the SYNTAX Study. Catheter Cardiovasc Interv. 2015;85(2):199-206. doi:10.1002/ccd.25545.

46. Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev. 2001;21(4):274-301. doi:10.1002/med.1010.

47. Benenati S, De Maria GL, Scarsini R, et al. Invasive “in the cath-lab” assessment of myocardial ischemia in patients with coronary artery disease: when does the gold standard not apply? Cardiovasc Revasc Med. 2018;19:362-72. doi:10.1016/j.carrev.2018.01.005.

48. Rajamannan NM. Osteocardiology. Cardiac bone formation. Springer. 2018. 110 p. ISBN: 978-3-319-64994-8.

49. Cailleaux PE, Blau D, Philippe L, et al. Biological secondary contributors to osteoporosis in fractured patients, is an early systematic assay relevant? Joint Bone Spine. 2019;86(6):777-81. doi:10.1016/j.jbspin.2019.03.009.

50. Tacey A, Qaradakhi T, Brennan-Speranza T, et al. Potential role for osteocalcin in the development of atherosclerosis and blood vessel disease. Nutrients. 2018;10(10):e1426. doi:10.3390/nu10101426.

51. New SE, Aikawa E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. Circ. Res. 2011;108(11):1381-91. doi:10.1161/CIRCRESAHA.110.234146.

52. Polonskaya YV, Kashanova EV, Murashov IS, et al. Associations of osteocalcin, osteoprotegerin, and calcitonin with inflammatory biomarkers in coronary artery atherosclerotic plaques. Bulletin of Experimental Biology and Medicine. 2016;162(12):691-4. (In Russ.)

53. Shibanova IA, Hryachkova ON. Use of biomarkers of phosphoric-calcium metabolism for the diagnosis and risk stratification of patients with coronary artery disease. RMJ. 2017;20:1409-14. (In Russ.)

54. Budoff MJ, Nasir K, Katz R. Thoracic aortic calcification and coronary heart disease events: the multi-ethnic study of atherosclerosis (MESA) Atherosclerosis. 2011;215:196-202. doi:10.1016/j.atherosclerosis.2010.11.017.

55. Song SO, Park K-W, Yoo S-H, et al. Association of coronary artery disease and atherosclerotic vascular fracture in Korean men and women. Endocrinol. Metab. 2012;27(1):39-44. doi:10.3803/EmM.2012.271.39.

56. An T, Hao J, Sun S, et al. Efficacy of statins for osteoporosis: a systematic review of mechanisms, animal models, and the prospects for therapy. J Bone Miner Res. 2016;31(1):175-88. doi:10.1002/jbmr.2962.

57. Kashtalap VV, Hryachkova ON. «New» pathological expansion. EuroIntervention. 2018;13:1430-4. doi:10.15829/1560-4071-2020